’s stock price has jumped by more than 20% after all patients in a trial of its Parkinson’s disease vaccine-like immunotherapy responded to the target antigen. On Thursday (14 November), the Switzerland-based pharma company saw its stock rise by 26.9% from market close on 13 November to the 14 November high.
The stock rose following the announcement of positive interim data from the of its anti-alpha-synuclein (a-syn) active immunotherapy candidate ACI-7104.056. The gold standard of business intelligence.
Not only did the data show positive antibody responses against the target antigen at six weeks, but the responses were strongly boostable. a-syn is believed to be a key protein in the disease due to its high prevalence in patients with Parkinson’s disease. Treatment with ACI-7104.
056 induced an increase in anti-a-syn antibodies on average 16-fold higher than the placebo background level after three immunisations. CEO of AC Immune, Dr. Andrea Pfeifer, said: “The level of immunogenicity after only three months of treatment as well as the continued positive safety profile, reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of Parkinson’s disease.
” VacSYn is an adaptive, placebo-controlled, and biomarker-based Phase II study in patients with early Parkinson’s disease, consisting of two parts with a seamless transition. Part 1 includes initial analyses from over 30 patients randomised to receive.
